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M Emberton1,2 and HU Ahmed1,2
OBJECTIVES: The rationale for directing targeted biopsy towards the centre of lesions has been questioned in light of prostate
cancer grade heterogeneity. In this study, we assess the assumption that the maximum cancer Gleason grade (Gleason grade
hotspot) lies within the maximum dimension (volume hotspot) of a prostate cancer lesion.
METHODS: 3-D histopathological models were reconstructed using the outputs of the 5-mm transperineal mapping (TPM) biopsies
used as the reference test in the pilot phase of Prostate Mri Imaging Study (PROMIS), a paired validating cohort study investigating
the performance of multi-parametric magnetic resonance imaging (MRI) against transrectal ultrasound (TRUS) biopsies. The
prostate was fully sampled with 5 mm intervals; each core was separately labelled, inked and orientated in space to register 3-D
cancer lesions location. The data from the histopathology results were used to create a 3-D interpolated reconstruction of each
lesion and identify the spatial coordinates of the largest dimension (volume hot spot) and highest Gleason grade (Gleason grade
hotspot) and assess their concordance.
RESULTS: Ninety-four men, with median age 62 years (interquartile range, IQR= 58–68) and median PSA 6.5 ng ml− 1 (4.6–8.8),
had a median of 80 (I69–89) cores each with a median of 4.5 positive cores (0–12). In the primary analysis, the prevalence of
homogeneous lesions was 148 (76%; 95% conﬁdence interval (CI) ± 6.0%). In all, 184 (94 ± 3.2%) lesions showed concordant
hotspots and 11/47 (23 ± 12.1%) of heterogeneous lesions showed discordant hotspots. The median 3-D distance between
discordant hotspots was 12.8 mm (9.9–15.5). These ﬁgures remained stable on secondary analyses using alternative reconstructive
assumptions. Limitations include a certain degree of error within reconstructed models.
CONCLUSIONS: Guiding one biopsy needle to the maximum cancer diameter would lead to correct Gleason grade attribution in
94% of all lesions and 79% of heterogeneous ones if a true hit was obtained. Further correlation of histological lesions, their MRI
appearance and the detectability of these hotspots on MRI will be undertaken once PROMIS results are released.
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INTRODUCTION
Correct risk attribution is of key importance to guide appropriate
management for men with prostate cancer. Our current diagnostic
pathway based on transrectal ultrasound (TRUS) guided biopsy
can result in inaccurate risk stratiﬁcation in up to half of all men
diagnosed.1 This can then result in missed diagnoses and under-
treatment as well as the more commonly recognised issues of
over-diagnosis and over-treatment.2–6
Recent research has focused on using multi-parametric
magnetic resonance imaging (mpMRI) to improve the diagnostic
accuracy by introducing tumour location at the time of biopsy.7–9
The provision of information on tumour location means that
biopsies can be directed to the region of interest rather than be
solely spread across the prostate as currently done with random
TRUS biopsies. Some have argued that the ‘targeted approach’
might result in employing fewer needle deployments than we
have previously used.10,11 If this is to happen—and it would be
desirable if it could—then we would need to know where within
the ‘target’ to direct those needles.
It is customary when presented with a target to direct the
needle to the centre of the target. However, some have raised
concerns that this strategy may not be optimal.12,13 Instead, it has
been argued that information acquired from imaging can identify
a particular area to target in order to obtain the most aggressive
component of one lesion which may not be.
To further explore this question, we have analysed data
obtained from the pilot phase of the MRC (Medical Research
Council)/HTA (Health Technology Assessment) Prostate Mri
Imaging Study (PROMIS), in which biopsy-naive men underwent
mpMRI followed by a transperineal template prostate mapping
(TPM) biopsy and TRUS biopsy. In this study, we attempted to
assess the validity of the premise that the largest dimension of a
tumour (volume hotspot) harbours the highest Gleason grade
(Gleason grade hotspot).
1Division of Surgery and Interventional Science, University College London, London, UK; 2Department of Urology, University College London Hospitals NHS Foundation Trust,
London, UK; 3Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 4Centre for Medical Image Computing, University College London, London,
UK; 5Department of Histopathology, College London Hospitals NHS Foundation Trust, London, UK; 6Medical Research Council Clinical Trials Unit, University College London,
London, UK and 7Department of Urology, Basingstoke Hospital, Hampshire Hospitals NHS Foundation Trust, Hampshire, UK. Correspondence: Dr A El-Shater Bosaily, Division of
Surgery and Interventional Science, University College London, 4th Floor, 132 Hampstead Road, London NW1 2BX, UK.
E-mail: a.shater@ucl.ac.uk or amshater@gmail.com
8These authors contributed equally to this work.
Received 25 October 2015; revised 30 December 2015; accepted 26 January 2016; published online 12 July 2016
Prostate Cancer and Prostatic Diseases (2016) 19, 258–263
www.nature.com/pcan
MATERIALS AND METHODS
Design of the PROMIS trial
PROMIS is a multicentre paired validating cohort study (Trial registry
identiﬁers: ISRCTN16082556, NCT01292291) funded by the UK NIHR
(National Institute of Health Research)—HTA programme and designed
to assess the diagnostic accuracy of an mpMRI-dependent pathway in
detection of clinically signiﬁcant prostate cancer.14
Biopsy-naive men who have been recommended a biopsy for suspicion of
prostate cancer (elevated PSA, abnormal digital rectal examination, family
history and/or ethnic risk group) are offered participation to the trial
(Table 1). After an informed consent is obtained, patients undergo a
standardised mpMRI (index test) protocol compliant to the European Society
of Urogenital Radiology guidelines15 followed by a combined biopsy
procedure involving TPM biopsy (reference test) and TRUS biopsy (standard
test) under general anaesthetic (Figure 1). MpMRI results are blinded to
clinicians performing the biopsies and to pathologists reporting the biopsy
results.
For the purpose of this work, we have used the histological outputs from
TPM biopsies conducted within the pilot phase of the trial. The pilot phase
was unique in permitting such an analysis as each individual core was
potted, processed and reported separately as well as oriented in space
(cranio-caudal and x-y plane). The full trial incorporated 5 mm sampling
but potted a number of cores together within prostate zones so would not
permit such an analysis as this. Imaging results and its correlation to
histology form the primary objective of the trial, we do not make any
reference to imaging ﬁndings within this paper as our aim is to asses the
validity of the premise that the highest Gleason score resides in the lesion’s
largest dimension, not if is consistent with a speciﬁc, identiﬁable imaging
phenotype.
TPM biopsy
TPM biopsy has been chosen as the reference standard to validate mpMRI
in PROMIS. It produces a histological map of the entire prostate in 3-
dimensions with an estimated sensitivity and negative predictive value of
around 95% (relative to prostatectomy) for clinically signiﬁcant cancer.16,17
In TPM, the prostate is sampled every 5 mm. This procedure has been
described in detail elsewhere.18 Only within the pilot phase of PROMIS,
each biopsy core was individually 3-D oriented in space in concordance to
its location in the prostate by recording the brachytherapy template grid
(‘x’ and ‘y’ planes) coordinates whilst the apical end of each core was
stained with India ink to identify its cranio-caudal orientation (‘z’ plane).
Each core was examined by an experienced uro-pathologist and
reported in terms of core length, Gleason score, high-grade prostatic
intraepithelial neoplasia and inﬂammation. The cancer core length (CCL)
was reported with the distance from the apical aspect of the core. Results
were plotted on a visual map with colour-coding to reﬂect the risk
stratiﬁcation derived from each core (Figures 2 and 3).19
This reporting format presents unprecedented detail and clarity in
recording the spatial position and relationship between positive cores,
their Gleason grades and estimated lesion volumes enabling us to
interpolate the results into a 3-D model.
Histological deﬁnitions
Volume hotspot. Volume hotspot is the coordinate in which if a biopsy
needle is deployed it will sample the largest dimension of the lesion and
return the longest CCL. The relationship between lesion volume and CCL is
well demonstrated in Ahmed et al.’s19 previous work, and it is the basis of
the lesion volume interpolation. It is determined across the sampling plane
(cranio-caudal) of a template biopsy rather than on maximum dimension
of the interpolated lesion, which may not be accessible from a TRUS or a
template approach hence does not contribute to patient risk stratiﬁcation.
Calculation of CCL. For the purpose of this study, decisions had to be
taken to deﬁne how the CCL is calculated. There is no consensus with
respect to which is the best method to deﬁne the CCL when discontinuous
foci of cancer are present within the same core. Based on a recent survey
around half pathologists consider that intervening benign tissue is not part
of the cancer (separate count), whereas the remaining half count CCL from
the initial part of the core with cancer to the end of the last cancer foci,
regardless of the amount of benign tissue in between (cumulative
count).20 In this study, we used separate counts within our primary analysis
but also secondarily evaluated the impact of using the cumulative count.
Table 1. PROMIS inclusion and exclusion criteria
Patient inclusion criteria
Men at least 18 years or over at risk of prostate cancer who have been advised to have a prostate biopsy
Serum PSA ⩽ 15ng ml− 1 within previous 3 months
Suspected stage ⩽ T2 on rectal examination (organ conﬁned)
Fit for general/spinal anaesthesia
Fit to undergo all protocol procedures including a transrectal ultrasound
Signed informed consent
Patient exclusion criteria
Treated using 5-alpha-reductase inhibitors at time of registration or during the prior 6 months
Previous history of prostate biopsy, prostate surgery or treatment for prostate cancer (interventions for BPH/bladder outﬂow obstruction are
acceptable)
Evidence of a urinary tract infection or history of acute prostatitis within the last 3 months
Contraindication to MRI (e.g., claustrophobia, pacemaker, estimated GFR ⩽ 50)
Any other medical condition precluding procedures described in the protocol
Previous history of hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work.
Abbreviations: GFR, glomerular ﬁltration rate; MRI, magnetic resonance imaging.
Combined Prostate Biopsy (CPB) Procedure 
Second: Transrectal Ultrasound (TRUS) guided biopsy
Visit 3 [As soon as possible after MRI]
First: Template Prostate Mapping (TPM) biopsy
Registration
Visit 1
Index test: MP-MRIVisit 2
Eligible
Patient identified with clinical suspicion of prostate cancer
Start: 0 
End: usually
<4 months Patients to follow standard care according to outcomes of tests
Visit 4
Results of all tests given to patients
End of study Follow up
(Report initially kept blind from patient and investigator)
Figure 1. Prostate Mri Imaging Study (PROMIS) trial schema. MP-MRI,
multi-parametric magnetic resonance imaging.
The concordance between the volume hotspot and the grade hotspot
A El-Shater Bosaily et al
259
Prostate Cancer and Prostatic Diseases (2016), 258 – 263
Gleason hotspot. Gleason hotspot is the coordinate in which if a biopsy
needle is deployed, it will capture the highest Gleason grade in the lesion
independent of the overall lesion volume or Gleason score.
A homogeneous lesion is deﬁned as a lesion compromised of only one
Gleason pattern, and hence both Gleason and volume hotspots are
inherently considered as concordant.
A heterogeneous lesion is deﬁned as a lesion composed of more than one
Gleason pattern, and hence the volume and Gleason grade hotspots may
not be at the same biopsy coordinates (non-Concordance).
On reporting biopsies, primary and secondary Gleason grade are
reported on the basis of relative percentage rather than on ﬁxed
quantitative thresholds. Therefore, in the case of one lesion generated
by the combination of various cores with the same total Gleason scores
(ex: Gleason 7) but different amounts of each grade pattern per core (ex:
Gleason 3+4, 40% grade 4), it is difﬁcult to determine whether there is or
there is not total Gleason score heterogeneity. For the purpose of our
primary analysis, we considered the presence of Gleason 3+4 and Gleason
4+3 in different areas of the same lesion was a criterion for heterogeneity
as there is some evidence that such a differentiation matters.21 For
secondary analyses, we also assumed heterogeneity within one lesion was
present only when different total Gleason scores were present on biopsy.
In other words, Gleason 4+3 and Gleason 3+4 within the same lesion were
considered as homogeneous.
3-Dimensional model/map
The 3-dimensional disease maps (Figures 4a and c) were reconstructed
using the detailed pathological results from all specimens. This enabled
the creation of a 3-D map which potentially has 13× 13× 40 sections of
pathological results (in terms of Gleason scores), as 13 × 13 (5 mm)
template grid holes are combined with two (apex and base) needle lengths
of 20 mm. Individual lesions were delineated on the reconstructed
13× 13× 40 map by using the rule of 26 connectivity. This means that
any block of positive samples is connected to 26 potential neighbour
blocks to form a single lesion. This map was then further reconstructed
into a ﬁner spatial resolution (0.5 × 0.5 × 0.5 mm3) by linear interpolation
followed by a Gaussian smoothing, whose single parameter of isotropic
variation was tuned so that the original histology results when re-sampled
at the same template grid sites will be preserved. This is the simplest
reconstruction algorithm from relatively sparse data maintaining the
clinical validity of reconstructed lesion maps. Simulations were performed
on the reconstructed map to get CCLs and Gleason scores and determine
their concordance. An animation of this modelling is available at https://
sites.google.com/site/yipenghu/gallery/template-biopsy-animation.
Figure 2. Transperineal mapping (TPM) histological ﬁndings per patient within the Prostate Mri Imaging Study (PROMIS) trial are resumed by a
full report and by a visual report. In the full report (a), each core is labelled per coordinate and the following details are displayed: core length,
cancer status, cumulative and separate cancer core length (CCL), cancer position, primary, secondary and tertiary Gleason grade, perineural
and lymphovascular invasion as well as the presence of inﬂammation, high-grade PIN and ASAP. The TPM visual report (b) provides immediate
zonal location within the gland. Maximum CCL and colour-coded risk attribution are displayed per coordinate with white boxes representing
prostate biopsies with no cancer. ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia.
Figure 3. UCL deﬁnitions of clinical signiﬁcance on transperineal
mapping (TPM) biopsy. Red indicates UCL deﬁnition 1 for signiﬁcant
disease (maximum cancer core length (MCCL)⩾ 6mm and/or
Gleason score⩾ 4+3). Yellow indicates UCL deﬁnition 2 for sig-
niﬁcant disease (MCCL⩾ 4mm and/or Gleason score⩾ 3+4) and
green deﬁnes insigniﬁcant disease (MCCL⩽ 3mm and Gleason
score⩽ 3+3). UCL, University College London.
Figure 4. (a–c) Disease maps showing two different lesions within
the same patient. One lesion (right side of the prostate; yellow)
shows homogeneous grade; therefore, the hotspots are considered
as concordant. The second lesion (left side of the prostate; scale of
colours) shows grade heterogeneity with the Gleason grade hotspot
located in the inferior right side of the lesion; therefore, the hotspots
are considered as discordant.
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Statistics
Descriptive statistics with continuous and categorical variables were
analysed using median with interquartile range (IQR), and frequencies with
percentages, respectively. Binomial 95% conﬁdence intervals (CIs) were
calculated. The data were analysed by statistical functions and procedures
for descriptive statistics and signiﬁcance testing, implemented in MATLAB
2014 (The MathWorks, Cambridge, UK) with Statistics Toolbox.
RESULTS
Overall, 129 men were enrolled in the pilot phase of PROMIS.
Thirty-ﬁve were excluded for various reasons: 19 chose to
withdraw; 12 because it was deemed not possible to sample the
entire prostate with a 5-mm density due to gland size; 3 due to co-
morbidities that developed before biopsy; and ﬁnally 1 due to
accidental un-blinding of his mpMRI. Therefore, 94 were included
in the present study. Patients’ characteristics are reported in
Table 2. Median age was 62 years (IQR = 58–68) and median PSA
was 6.5 ng ml− 1 (4.6–8.8). A median of 80 cores (69–89) were
taken per patient with a median of 4.5 positive cores (0–12).
Median maximum cancer core length (MCCL) was 3 mm, both
when using a cumulative (0–8) and a separate (0–7) CCL count. An
example of a TPM report is given in Figure 2.
Primary analyses: for our primary analyses, which used the
separate criteria for deﬁning MCCL and Gleason grades, 195
independent lesions were detected (Table 3). The overall
prevalence of homogeneous lesions was 148 (95%CI 76 ± 6.0%).
Most of these lesions had a Gleason score 3+3 (n= 119; 61 ± 6.9%),
fewer had a Gleason score 3+4 (n= 66; 34 ± 6.6%), and a minority
had a Gleason score 4+3 (n= 10; 5 ± 3.1%). Median lesion volume
was 0.075 ml (0.025–0.225). Discordant hotspots were present in
11/47 (23 ± 12.1%). The median 3-D distance between the
hotspots when they were discordant was 12.8 mm (9.9–15.5).
Overall, considering both homogeneous and heterogeneous
lesions together, 184/195 (94 ± 3.2%) of lesions harboured the
Gleason grade hotspot in the volume hotspot.
Secondary analyses: Using separate criteria for deﬁning the
MCCL and the overall score to deﬁne heterogeneity, the results
remained stable. Discordant hotspots were present in 10/43
(23 ± 12.6%); the median 3-D distance between hotspots when
they were discordant was 12.5 mm (9.9–15.8).
When the histology outputs were reconstructed to determine
the 3-D models using the cumulative method to assign CCL, 190
independent lesions were found (Table 3). Most of these lesions
had a Gleason score 3+3 (n= 118; 62 ± 6.9%), fewer had a Gleason
score 3+4 (n= 64; 34 ± 6.7%), and a minority a Gleason score 4+3
(n= 8; 4 ± 2.9%). Median lesion volume was 0.075 ml (0.025–0.275).
Between 144 (76 ± 6.1%) and 148 (78 ± 5.9%) lesions were
considered as homogeneous, according to the deﬁnition of grade
heterogeneity used. Of the remaining heterogeneous lesions,
33/42 (79 ± 12.4%) and 34/46 (74 ± 12.7%) had Gleason grade
hotspots that were concordant to the volume hotspots. The
median 3-D distance in the discordant lesions was 9.9 mm (9.8–
15.3) and 11.5 mm (9.9–14), respectively.
The overall concordance rates of all secondary analyses when
including all lesions were not different compared with the primary
analysis.
DISCUSSION
In summary, we have shown that the Gleason grade hotspot for a
lesion is concordant with the volume hotspot in over 9 in 10 of all
lesions. We also found that in biopsy-naive men, about one in ﬁve
lesions are heterogeneous in grade. For these lesions, the Gleason
grade and volume hotspot are discordant in about 2 in 10 lesions
with approximately 10 mm distance between the two.
Before discussing the clinical implications of our ﬁndings, there
are some limitations that need to be addressed. First, while this is a
Table 2. Patients’ characteristics
Variable Value
No. of patients 94
Age, years, median (IQR) 62 (58, 68)
PSA, ng ml− 1, median (IQR) 6.5 (4.6, 8.8)
Total no. of cores, median (IQR) 80 (69, 89)
No. of positive cores, median (IQR) 4.5 (0, 12)
Cancer core length (separate count), median (IQR) 3 (0, 8)
Cancer core length (cumulative count), median (IQR) 3 (0, 7)
Abbreviation: IQR, interquartile range.
Table 3. Results of analysis after interpolation
Variable Primary analysis Secondary analysis








No. of independent lesions 195 195 190 190
Gleason score, no (±95% CI)
3+3 119 (61± 6.9%) 119 (61± 6.9%) 118 (62± 6.9%) 118 (62± 6.9%)
3+4 66 (34± 6.6%) 66 (34± 6.6%) 64 (34± 6.7%) 64 (34± 6.7%)
4+3 10 (5± 3.1%) 10 (5± 3.1%) 8 (4± 2.9%) 8 (4± 2.9%)
Lesion volume, ml, median 0.075 0.075 0.075 0.075
IQR (0.025–0.225) (0.025–0.225) (0.025–0.275) (0.025–0.275)
Range (0.025–6.200) (0.025–6.200) (0.025–8.275) (0.025–8.275)
Homogeneous lesions, no. (±95% CI) 148 (76± 6.0%) 152 (78± 5.8%) 144 (76± 6.1%) 148 (78± 5.9%)
Heterogeneous lesions, no. (±95% CI) 47 (24± 6.0%) 43 (22± 5.8%) 46 (24± 6.1%) 42 (22± 5.9%)
Heterogeneous lesions with concordant
hotspots, no. (±95% CI)
36/47 (77± 12.1%) 33/43 (77± 12.6%) 34/46 (74± 12.7%) 33/42 (79± 12.4%)
Heterogeneous lesions with no concordant
hotspots, no. (±95% CI)
11/47 (23± 12.1%) 10/43 (23± 12.6%) 12/46 (26± 12.7%) 9/42 (21± 12.4%)
3-D hotspots distance in heterogeneous non-concordant
lesions, mm, median (IQR)
12.8 (9.9–15.5) 12.5 (9.9–15.8) 11.5 (9.9–14.0) 9.9 (9.8–15.3)
Total number of concordant lesions (±95% CI) 184/195 (94± 3.2%) 185/195 (95± 3.1%) 178/190 (94± 3.5%) 181/190 (95± 3.0%)
Abbreviations: CCL, cancer core length; CI, conﬁdence interval; IQR, interquartile range.
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computer reconstruction based on precise 3-D pathology data, a
certain degree of error is inevitable. It is possible that some very
small lesions might have been missed, and the clustering of some
lesions might have been incorrect. To minimise these errors, we
used two methods for determining whether positive biopsies
belonged to one speciﬁc lesion or not; this had minimal impact on
our ﬁndings.
Second, these ﬁndings may be valid in this study population of
biopsy-naive men with early suspicion of prostate cancer and PSA
less than 15 ng ml− 1, but it is likely, and it has been indeed
previously shown that greater heterogeneity is present in men
with more advanced disease.22,23
Third, some may argue that radical prostatectomy specimen
analysis should be used as a reference test within the trial.
Although we have already clariﬁed the reasons for choosing TPM
biopsy as the reference test within the PROMIS trial elsewhere,14
we would argue that TPM biopsy represents a more valid tool as it
can avoid the selection bias towards higher disease burden
associated with the use of radical prostatectomy as a reference
test. This is especially true in this subgroup of biopsy-naive men, in
which a minority are expected to undergo radical prostatectomy.
Finally, our study was limited to the 94 men included in the
pilot phase of the trial. Although this is an embedded study with
no power calculation upfront, the PROMIS TMG approved this
study as these very detailed 3-D histopathological maps could be
built only for this subgroup of men, and awaiting trial completion
would not add additional data to this study. Indeed, while patients
recruited after the pilot phase had the same TPM procedure, there
was a lack of some spatial information which are of key
importance for the purpose of this study (core inking and precise
3-D orientation). This change in the histopathological analysis was
due to resources and cost implications.
Clinical implications
Precise risk stratiﬁcation remains a challenge. In a disease such as
prostate cancer that exhibits such a degree of heterogeneity, and
in which the course of the disease appears to be deﬁned by the
dominant Gleason pattern, the provision of tissue that enables its
identiﬁcation remains a key.24 The role of image-targeted biopsies
has come to the fore as a way of possibly improving risk
stratiﬁcation. Targeted biopsies can be carried out in three
possible ways: ﬁrst, visually targeted, second using image-fusion
software and third, in-bore (within the scanner). Recently, some
have challenged the use of MRI to ultrasound registration, which
currently directs the urologist’s needle to the centre of a lesion by
assuming that the most aggressive part of the tumour might not
be in the centre of the lesion.12 One study showed that the most
aggressive part of the prostate is not necessarily in the centre, and
therefore the authors suggested targeted biopsies are best carried
out in-bore. Our ﬁndings are somewhat contrasting to this report.
We believe there might be some reasons for this discrepancy. First,
the authors selected only men undergoing radical prostatectomy.
We know that the larger the tumour the greater the
heterogeneity.22,23 This can be due to branching of a clone into
different distinct phenotypes, but it can also be due to two
adjacent, but clonally independent tumours, merging to form
one.22,25 Second, the authors based their results on retrospective
radiological ﬁndings of diffusion coefﬁcient heterogeneity, which
does not always correspond to true histological heterogeneity.26,27
Our study implies that the method of targeting and deploying a
needle towards the centre of a lesion would lead to correct risk
stratiﬁcation in the vast majority. This reinforces the idea that MRI
to ultrasound registration might be adequate to achieve correctly
sampling, although the number of needles to be used to achieve a
true hit in the centre of the tumour is yet to be determined taking
into account that registration and operator errors can occur as
well as dynamic swelling in between each needle deployment.
Some early evidence from our group points to increasing accuracy
of detection using up to ﬁve needle deployments per target.28
CONCLUSION
Our study demonstrates that guiding one biopsy needle to the
maximum cancer diameter would lead to correct grade attribution
in the majority of all lesions and approximately 80% of lesions
heterogeneous for Gleason grade. Correlation of these histological
lesions to their MRI appearance as well as the optimal biopsy
needle deployment protocol requires further research.
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